Evident, a wholly-owned subsidiary of Olympus Corporation is partnering with Corista to deliver digital pathology capabilities to clients worldwide
CONCORD, Mass., August 11, 2022 /PRNewswire-PRWeb/ -- Corista announces the collaboration with Evident, a wholly-owned subsidiary of Olympus Corporation extending enhanced digital pathology capabilities to clients worldwide.
Formerly the Scientific Solutions division of Olympus Corporation, Evident chose to partner with Corista in response to customer needs for expanded digital pathology capabilities. Corista's DP3 is the digital pathology software platform of choice for major medical organizations seeking advanced clinical, research, and educational capabilities.
"We're excited about this collaboration," said Corista Founder & CEO Elizabeth Wingard, "Pathologists face unique challenges and with Corista's platforms in place, Evident's clients can operate more efficiently in a fully digital environment."
Collaborating with Corista offers expansive capabilities to Evident's customers: pathologists can streamline complex workflows, efficiently manage clinical case reviews and analysis, and closely collaborate with colleagues worldwide on shared cases.
"Evident's continued goal is to deliver our products and services that elevate the standard of healthcare and other professional works," said Evident Head of Life Science Strategy Motoki Inoue. "Through this collaboration with Corista, we expect our customers will realize even greater efficiencies through a seamless and integrated pathology experience. "
About Corista
Corista delivers the industry's most extensive array of workflow, analytical and collaborative tools for pathology. Medical centers can seamlessly integrate with LIS/EHRs in a unified digital environment of whole-slide, gross and static pathology images. Physicians have 21st-century tools to collaborate, communicate, teach, and report with access to 'best of breed' image analytics. Specialists can receive digital consults from remote physicians and patients from across the globe, and investigator-initiated researchers have a research and development platform to develop and apply their algorithms. Corista provides for a new level of interoperability for pathology, integrating whole slide image scanning systems, image analytics, and LIS/EHR platforms with a rich, collaborative environment for physicians, patients, biotech, and pharmaceutical scientists. This is Integrated Pathology™ only from Corista. For more information, visit https://corista.com/.
About Evident
At Evident, we are guided by the scientific spirit—innovation and exploration are at the heart of what we do. Committed to making people's lives healthier, safer, and more fulfilling, we support our customers with solutions that solve their challenges and advance their work; whether it's researching medical breakthroughs, inspecting infrastructure, or exposing hidden toxins in consumer products. Evident Life Science empowers scientists and researchers through collaboration and cutting-edge life science solutions. Dedicated to meeting the challenges and supporting the evolving needs of its customers, Evident Life Science advances a comprehensive range of microscopes for pathology, hematology, IVF, and other clinical applications as well as for research and education. For more information, visit EvidentScientific.com.
Media Contact
Anne Marsden, Corista, 1 6785751045, [email protected]
SOURCE Corista
Share this article